Caribou Biosciences (CRBU) Operating Expenses (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Operating Expenses of $28.7 million for Q1 2026, down 36.65% year-over-year from $45.3 million in Q1 2025, and down 11.47% quarter-over-quarter from $32.4 million in Q4 2025.
Caribou Biosciences (CRBU) Operating Expenses (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Operating Expenses for 7 consecutive years, with $28.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 36.65% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $142.9 million (down 17.6% YoY), while the FY2025 annual figure was $159.5 million, down 9.69% from the prior year.
- Operating Expenses eased to $28.7 million in Q1 2026 per CRBU's latest filing, from $32.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $50.2 million in Q2 2025 and bottomed at $23.5 million in Q1 2022.
- Historically, Operating Expenses has averaged $37.4 million across 5 years, with a median of $36.6 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 87.06% — and 2026, when it slumped 36.65%.
- Caribou Biosciences' Operating Expenses stood at $34.3 million in 2022, then gained by 19.64% to $41.0 million in 2023, then decreased by 0.12% to $41.0 million in 2024, then dropped by 20.9% to $32.4 million in 2025, then fell by 11.47% to $28.7 million in 2026.
- Business Quant data shows CRBU's Operating Expenses at $28.7 million in Q1 2026, $32.4 million in Q4 2025, and $31.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Caribou Biosciences | 165.11 Mn | 52.80 Mn | - | 26.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.84 Mn |
| Mar 31, 2026 | 28.68 Mn |
| Dec 31, 2025 | 32.39 Mn |
| Sep 30, 2025 | 31.60 Mn |
| Jun 30, 2025 | 50.25 Mn |
| Mar 31, 2025 | 45.27 Mn |
| Dec 31, 2024 | 40.95 Mn |
| Sep 30, 2024 | 40.26 Mn |
| Jun 30, 2024 | 46.97 Mn |
| Mar 31, 2024 | 48.43 Mn |
| Dec 31, 2023 | 41.00 Mn |
| Sep 30, 2023 | 38.30 Mn |
| Jun 30, 2023 | 36.62 Mn |
| Mar 31, 2023 | 34.62 Mn |
| Dec 31, 2022 | 34.27 Mn |
| Sep 30, 2022 | 29.84 Mn |
| Jun 30, 2022 | 32.62 Mn |
| Mar 31, 2022 | 23.52 Mn |
| Dec 31, 2021 | 22.96 Mn |
| Sep 30, 2021 | 22.59 Mn |